Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1959MR)

This product GTTS-WQ1959MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1959MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1885MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ3713MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ2975MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ12078MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ5848MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ2937MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ11176MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ4356MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW